Senjuti Kabir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Senjuti Kabir has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Sayera Banu
Infectious Diseases Division, icddr,b, Dhaka, Bangladesh
13 shared publications - Shahriar Ahmed
Infectious Diseases Division, icddr,b, Dhaka, Bangladesh
10 shared publications - Syed Mohammad Mazidur Rahman
Infectious Diseases Division, icddr,b, Dhaka, Bangladesh
9 shared publications - Mohammad Khaja Mafij Uddin
Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Dhaka 1212, Bangladesh
6 shared publications - Tanjina Rahman
Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Dhaka 1212, Bangladesh
4 shared publications - Arfatur Rahman
Affiliation icddr,b, Dhaka, Bangladesh
3 shared publications
Latest Publications
- Open Access
Pooled sputum testing for the detection of pulmonary tuberculosis by Xpert ® MTB/RIF Ultra: a multi-site cross-sectional diagnostic evaluation study in Bangladesh
Background: Xpert ® MTB/RIF Ultra (Xpert Ultra) is a WHO recommended molecular test for rapid tuberculosis (TB) detection, but cartridge cost limits large-scale use of Xpert Ultra in high TB burden, resource-constrained countries. This study assessed the diagnostic performance of Xpert Ultra on pooled sputum for detection of pulmonary TB (PTB)in Bangladesh. Methods: Between July 2024 and February 2025, adults with presumptive PTB were prospectively enrolled from primary and secondary healthcare facilities through facility-based case finding, and from urban slum communities through community-based case finding. Participants provided two sputum samples, one for individual and pooled Xpert Ultra testing, and another for culture. Pooled and individual Xpert Ultra results were compared to the microbiological reference standard of culture. Cost analysis was performed by comparing cartridge usage between individual and pooled Xpert Ultra testing. Results: A total of 3043 individuals were tested individually and as part of 771 pooled samples. Compared with culture, the overall sensitivities of pooled and individual Xpert Ultra were 85.8% (95% CI: 79.8-90.6) and 89.2% (83.7-93.4), respectively, while specificities were 98.9% (98.4-99.2) and 98.1% (97.5-98.6). Pooled Xpert Ultra detected 100% of the high, medium, and low burden categories identified by individual testing, but showed lower detection for very low (81.8%) and trace (31.4%). Compared with individual testing, pooled testing reduced cartridge use and cost by 55.8%. Conclusions: Pooled sputum testing with Xpert Ultra demonstrated high diagnostic performance similar to individual testing, while substantially reducing the cartridge costs. This approach offers a scalable molecular TB testing in resource-limited, high-burden countries such as Bangladesh.
Open AccessPooled sputum testing for the detection of pulmonary tuberculosis by Xpert ® MTB/RIF Ultra: a multi-site cross-sectional diagnostic evaluation study in Bangladesh
Background: Xpert ® MTB/RIF Ultra (Xpert Ultra) is a WHO recommended molecular test for rapid tuberculosis (TB) detection, but cartridge cost limits large-scale use of Xpert Ultra in high TB burden, resource-constrained countries. This study assessed the diagnostic performance of Xpert Ultra on pooled sputum for detection of pulmonary TB (PTB)in Bangladesh. Methods: Between July 2024 and February 2025, adults with presumptive PTB were prospectively enrolled from primary and secondary healthcare facilities through facility-based case finding, and from urban slum communities through community-based case finding. Participants provided two sputum samples, one for individual and pooled Xpert Ultra testing, and another for culture. Pooled and individual Xpert Ultra results were compared to the microbiological reference standard of culture. Cost analysis was performed by comparing cartridge usage between individual and pooled Xpert Ultra testing. Results: A total of 3043 individuals were tested individually and as part of 771 pooled samples. Compared with culture, the overall sensitivities of pooled and individual Xpert Ultra were 85.8% (95% CI: 79.8-90.6) and 89.2% (83.7-93.4), respectively, while specificities were 98.9% (98.4-99.2) and 98.1% (97.5-98.6). Pooled Xpert Ultra detected 100% of the high, medium, and low burden categories identified by individual testing, but showed lower detection for very low (81.8%) and trace (31.4%). Compared with individual testing, pooled testing reduced cartridge use and cost by 55.8%. Conclusions: Pooled sputum testing with Xpert Ultra demonstrated high diagnostic performance similar to individual testing, while substantially reducing the cartridge costs. This approach offers a scalable molecular TB testing in resource-limited, high-burden countries such as Bangladesh.
- Open Access
- 9 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 603
Evaluation of a Fluorescence Immunoassay-Based IGRA for Latent Tuberculosis Diagnosis: A Simplified, Cost-Effective Alternative
Approximately 25% of the global population is estimated to have latent tuberculosis infection (LTBI), with a 5–10% lifetime risk of progression to active disease. Although interferon-gamma release assays (IGRAs) are widely used for LTBI diagnosis, their high cost and operational complexity limit large-scale implementation in resource-limited settings. This study evaluated the diagnostic performance of a low-complexity, rapid, fluorescence-based point-of-care assay, ichroma IGRA-TB, for LTBI detection. A total of 300 participants enrolled at TB Screening and Treatment Centers and the Dhaka Hospital of icddr,b were categorized as healthy controls (n = 130), household contacts of TB patients (n = 70), GeneXpert MTB/RIF Ultra-positive active TB patients (n = 80), or individuals with a previous history of TB (n = 20). ichroma IGRA-TB was compared with QuantiFERON-TB Gold Plus (QFT-Plus) across all groups. Overall agreement between ichroma IGRA-TB and QFT-Plus was 91.9%, with a Cohen’s kappa of 0.83, indicating almost perfect concordance. Using culture as a surrogate reference standard, QFT-Plus demonstrated higher sensitivity (74.6%) than ichroma IGRA-TB (69.0%). Overall, ichroma IGRA-TB demonstrates high agreement with QFT-Plus and acceptable sensitivity, supporting its potential as a near-point-of-care tool for LTBI screening in resource-constrained settings.
- 9 March 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (3) , 603
Open AccessEvaluation of a Fluorescence Immunoassay-Based IGRA for Latent Tuberculosis Diagnosis: A Simplified, Cost-Effective Alternative
Approximately 25% of the global population is estimated to have latent tuberculosis infection (LTBI), with a 5–10% lifetime risk of progression to active disease. Although interferon-gamma release assays (IGRAs) are widely used for LTBI diagnosis, their high cost and operational complexity limit large-scale implementation in resource-limited settings. This study evaluated the diagnostic performance of a low-complexity, rapid, fluorescence-based point-of-care assay, ichroma IGRA-TB, for LTBI detection. A total of 300 participants enrolled at TB Screening and Treatment Centers and the Dhaka Hospital of icddr,b were categorized as healthy controls (n = 130), household contacts of TB patients (n = 70), GeneXpert MTB/RIF Ultra-positive active TB patients (n = 80), or individuals with a previous history of TB (n = 20). ichroma IGRA-TB was compared with QuantiFERON-TB Gold Plus (QFT-Plus) across all groups. Overall agreement between ichroma IGRA-TB and QFT-Plus was 91.9%, with a Cohen’s kappa of 0.83, indicating almost perfect concordance. Using culture as a surrogate reference standard, QFT-Plus demonstrated higher sensitivity (74.6%) than ichroma IGRA-TB (69.0%). Overall, ichroma IGRA-TB demonstrates high agreement with QFT-Plus and acceptable sensitivity, supporting its potential as a near-point-of-care tool for LTBI screening in resource-constrained settings.
- Open Access
- 21 January 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (2) , 338
Centrifugation Versus Centrifugation-Free Stool Processing: Can the Simple One-Step Method Reliably Diagnose Pediatric Pulmonary Tuberculosis Using Xpert MTB/RIF Ultra?
Background/Objectives: Stool-based GeneXpert testing has become a useful approach for diagnosing pediatric pulmonary tuberculosis (PTB). This study compared two stool-processing methods, centrifugation-based processing (CBP) and simple one-step (SOS), for detecting PTB in children using Xpert MTB/RIF Ultra (Ultra). Methods: Children with presumptive PTB were screened cross-sectionally, and stool samples were collected and tested with Ultra using the CBP method from March 2022 to December 2024 across seven divisions of Bangladesh. A subset of stool samples (n = 281) that tested positive (n = 191) and negative (n = 90) by the CBP method were re-tested again with the same sample by Ultra using the SOS method. The results of the Ultra with SOS-processed stool were compared with the CBP method to evaluate overall agreement and detection efficiency across different bacterial burdens. Results: The SOS method detected 97 of 191 CBP-positive samples, resulting in a positive percentage agreement of 50.8% (95% CI: 43.5–58.1). All 90 Ultra-negative stool were also negative by the SOS method, yielding a negative percentage agreement of 100% (95% CI: 96.0–100.0). Overall agreement between the methods was 66.6% (Kappa: 0.398). The SOS method detected 100% of high- (4/4) and medium- (7/7), 97.3% (36/37) of low-, and 83.3% (35/42) of very-low-bacterial-burden samples, but only 14.9% (15/101) of the trace-detected samples that were identified by the CBP method. Conclusions: Stool testing with Ultra using the SOS processing method missed a significant number of the most prevalent form of child TB—the ‘trace-detected’ category identified by the CBP method. For increased detection of childhood TB nationwide, the national program should prioritize the use of Ultra on stool samples processed by the CBP method.
- 21 January 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (2) , 338
Open AccessCentrifugation Versus Centrifugation-Free Stool Processing: Can the Simple One-Step Method Reliably Diagnose Pediatric Pulmonary Tuberculosis Using Xpert MTB/RIF Ultra?
Background/Objectives: Stool-based GeneXpert testing has become a useful approach for diagnosing pediatric pulmonary tuberculosis (PTB). This study compared two stool-processing methods, centrifugation-based processing (CBP) and simple one-step (SOS), for detecting PTB in children using Xpert MTB/RIF Ultra (Ultra). Methods: Children with presumptive PTB were screened cross-sectionally, and stool samples were collected and tested with Ultra using the CBP method from March 2022 to December 2024 across seven divisions of Bangladesh. A subset of stool samples (n = 281) that tested positive (n = 191) and negative (n = 90) by the CBP method were re-tested again with the same sample by Ultra using the SOS method. The results of the Ultra with SOS-processed stool were compared with the CBP method to evaluate overall agreement and detection efficiency across different bacterial burdens. Results: The SOS method detected 97 of 191 CBP-positive samples, resulting in a positive percentage agreement of 50.8% (95% CI: 43.5–58.1). All 90 Ultra-negative stool were also negative by the SOS method, yielding a negative percentage agreement of 100% (95% CI: 96.0–100.0). Overall agreement between the methods was 66.6% (Kappa: 0.398). The SOS method detected 100% of high- (4/4) and medium- (7/7), 97.3% (36/37) of low-, and 83.3% (35/42) of very-low-bacterial-burden samples, but only 14.9% (15/101) of the trace-detected samples that were identified by the CBP method. Conclusions: Stool testing with Ultra using the SOS processing method missed a significant number of the most prevalent form of child TB—the ‘trace-detected’ category identified by the CBP method. For increased detection of childhood TB nationwide, the national program should prioritize the use of Ultra on stool samples processed by the CBP method.
- Open Access
- 15 July 2025
- Published by Elsevier in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- Vol. 40, 100552
OMNIgene.SPUTUM for transporting sputum in ambient temperature for tuberculosis testing: Bangladesh experience
- 15 July 2025
- Published by Elsevier in Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
- Vol. 40, 100552
Open AccessOMNIgene.SPUTUM for transporting sputum in ambient temperature for tuberculosis testing: Bangladesh experience
- Open Access
A study protocol on assessing the acceptance and effectiveness of a digital adherence technology for TB preventive treatment in Bangladesh
Background: Adherence to tuberculosis preventive treatment (TPT) remains a significant challenge in high-burden countries like Bangladesh, where approximately 44 million people are infected with latent tuberculosis. Methods/Design: This study protocol describes a mixed-methods observational study to evaluate “iDOTS,” a locally developed digital adherence technology adapted from 99DOTS, for monitoring and improving TPT adherence among adult household contacts of bacteriologically confirmed pulmonary TB patients. The study will be conducted in two districts in Bangladesh with similar geographical and societal characteristics, with Narsingdi as the intervention site and Manikganj as the control site. Applying the Unified Theory of Acceptance and Use of Technology (UTAUT), we will assess technology acceptance, implementation challenges, and effectiveness through quantitative and qualitative approaches. The quantitative component will compare TPT adherence between iDOTS users and non-users, while qualitative interviews will explore user experiences and attitudes among healthcare providers and patients. Adherence will be verified through a combination of digital records, self-reports, and random isoniazid urine testing. Discussion: With an estimated sample size of 422 patients and 77 healthcare providers, this study aims to generate evidence that if digital adherence technologies can strengthen TPT implementation in resource-limited settings. The findings will address critical gaps in the TPT cascade and inform strategies for scaling up TPT nationally, ultimately supporting global efforts to reduce the TB disease burden through effective preventive measures. Trial registration: ‘Not applicable’
Open AccessA study protocol on assessing the acceptance and effectiveness of a digital adherence technology for TB preventive treatment in Bangladesh
Background: Adherence to tuberculosis preventive treatment (TPT) remains a significant challenge in high-burden countries like Bangladesh, where approximately 44 million people are infected with latent tuberculosis. Methods/Design: This study protocol describes a mixed-methods observational study to evaluate “iDOTS,” a locally developed digital adherence technology adapted from 99DOTS, for monitoring and improving TPT adherence among adult household contacts of bacteriologically confirmed pulmonary TB patients. The study will be conducted in two districts in Bangladesh with similar geographical and societal characteristics, with Narsingdi as the intervention site and Manikganj as the control site. Applying the Unified Theory of Acceptance and Use of Technology (UTAUT), we will assess technology acceptance, implementation challenges, and effectiveness through quantitative and qualitative approaches. The quantitative component will compare TPT adherence between iDOTS users and non-users, while qualitative interviews will explore user experiences and attitudes among healthcare providers and patients. Adherence will be verified through a combination of digital records, self-reports, and random isoniazid urine testing. Discussion: With an estimated sample size of 422 patients and 77 healthcare providers, this study aims to generate evidence that if digital adherence technologies can strengthen TPT implementation in resource-limited settings. The findings will address critical gaps in the TPT cascade and inform strategies for scaling up TPT nationally, ultimately supporting global efforts to reduce the TB disease burden through effective preventive measures. Trial registration: ‘Not applicable’
- Open Access
- 19 April 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (4) , 1066
Diagnostic Performance of Different Laboratory Methods for the Detection of Extrapulmonary Tuberculosis
Accurate and appropriate extrapulmonary tuberculosis (EPTB) diagnosis remains challenging due to its paucibacillary nature, requirement of invasive collection procedures, and lack of sensitive tests. This study investigated the diagnostic performance of different methods for the diagnosis of EPTB. A total of 1340 EPTB specimens were collected from presumptive EPTB patients from four different hospitals between November 2015 and March 2017. The collected specimens were tested with AFB microscopy, culture, Xpert MTB/RIF assay (Xpert), and MTBDRplus assay. Among the 1340 EPTB specimens, 49 (3.66%), 141 (10.52%), 166 (12.39%), and 154 (11.49%) were positive in AFB microscopy, culture, Xpert MTB/RIF, and MTBDRplus assay, respectively. A total of 194 (14.9%) cases were found positive in at least one of these methods. Using culture as a reference standard, the sensitivity and specificity of AFB microscopy, Xpert MTB/RIF, and MTBDRplus assay were: 27.0%/99.1%, 83.7%/96.0%, and 79.4%/96.5%, respectively. Compared to the composite reference standard, the sensitivity of culture, AFB microscopy, Xpert MTB/RIF, and MTBDRplus assay was 72.7%, 25.3%, 85.6%, and 79.4%, respectively, with a specificity of 100% for all the methods. The Xpert MTB/RIF assay showed the highest sensitivity compared to other methods. Considering the short turnaround time and promising findings, Xpert MTB/RIF assay should be integrated into national TB guidelines as a routine diagnostic test.
- 19 April 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (4) , 1066
Open AccessDiagnostic Performance of Different Laboratory Methods for the Detection of Extrapulmonary Tuberculosis
Accurate and appropriate extrapulmonary tuberculosis (EPTB) diagnosis remains challenging due to its paucibacillary nature, requirement of invasive collection procedures, and lack of sensitive tests. This study investigated the diagnostic performance of different methods for the diagnosis of EPTB. A total of 1340 EPTB specimens were collected from presumptive EPTB patients from four different hospitals between November 2015 and March 2017. The collected specimens were tested with AFB microscopy, culture, Xpert MTB/RIF assay (Xpert), and MTBDRplus assay. Among the 1340 EPTB specimens, 49 (3.66%), 141 (10.52%), 166 (12.39%), and 154 (11.49%) were positive in AFB microscopy, culture, Xpert MTB/RIF, and MTBDRplus assay, respectively. A total of 194 (14.9%) cases were found positive in at least one of these methods. Using culture as a reference standard, the sensitivity and specificity of AFB microscopy, Xpert MTB/RIF, and MTBDRplus assay were: 27.0%/99.1%, 83.7%/96.0%, and 79.4%/96.5%, respectively. Compared to the composite reference standard, the sensitivity of culture, AFB microscopy, Xpert MTB/RIF, and MTBDRplus assay was 72.7%, 25.3%, 85.6%, and 79.4%, respectively, with a specificity of 100% for all the methods. The Xpert MTB/RIF assay showed the highest sensitivity compared to other methods. Considering the short turnaround time and promising findings, Xpert MTB/RIF assay should be integrated into national TB guidelines as a routine diagnostic test.
- Open Access
- 1 January 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 114, 244-251
Xpert MTB/RIF Ultra assay for the detection of Mycobacterium tuberculosis in people with negative conventional Xpert MTB/RIF but chest imaging suggestive of tuberculosis in Dhaka, Bangladesh
- 1 January 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 114, 244-251
Open AccessXpert MTB/RIF Ultra assay for the detection of Mycobacterium tuberculosis in people with negative conventional Xpert MTB/RIF but chest imaging suggestive of tuberculosis in Dhaka, Bangladesh
- Open Access
- 1 November 2021
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 95, 105052
Genetic diversity and characterization of M. tuberculosis isolates causing extrapulmonary tuberculosis in Bangladesh
- 1 November 2021
- Published by Elsevier in Infection, Genetics and Evolution
- Vol. 95, 105052
Open AccessGenetic diversity and characterization of M. tuberculosis isolates causing extrapulmonary tuberculosis in Bangladesh
- Open Access
- 23 November 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (11) , e0241437
Social Enterprise Model (SEM) for private sector tuberculosis screening and care in Bangladesh
Background: In Bangladesh, about 80% of healthcare is provided by the private sector. Although free diagnosis and care is offered in the public sector, only half of the estimated number of people with tuberculosis are diagnosed, treated, and notified to the national program. Private sector engagement strategies often have been small scale and time limited. We evaluated a Social Enterprise Model combining external funding and income generation at three tuberculosis screening centres across the Dhaka Metropolitan Area for diagnosing and treating tuberculosis. Methods and findings: The model established three tuberculosis screening centres across Dhaka Metropolitan Area that carried the icddr,b brand and offered free Xpert MTB/RIF tests to patients visiting the screening centres for subsidized, digital chest radiographs from April 2014 to December 2017. A network of private and public health care providers, and community recommendation was formed for patient referral. No financial incentives were offered to physicians for referrals. Revenues from radiography were used to support screening centres’ operation. Tuberculosis patients could choose to receive treatment from the private or public sector. Between 2014 and 2017, 1,032 private facilities networked with 8,466 private providers were mapped within the Dhaka Metropolitan Area. 64, 031 patients with TB symptoms were referred by the private providers, public sector and community residents to the three screening centres with 80% coming from private providers. 4,270 private providers made at least one referral. Overall, 10,288 pulmonary and extra-pulmonary tuberculosis cases were detected and 7,695 were bacteriologically positive by Xpert, corresponding to 28% of the total notifications in Dhaka Metropolitan Area. Conclusion: The model established a network of private providers who referred individuals with presumptive tuberculosis without financial incentives to icddr,b’s screening centres, facilitating a quarter of total tuberculosis notifications in Dhaka Metropolitan Area. Scaling up this approach may enhance national and international tuberculosis response.
- 23 November 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (11) , e0241437
Open AccessSocial Enterprise Model (SEM) for private sector tuberculosis screening and care in Bangladesh
Background: In Bangladesh, about 80% of healthcare is provided by the private sector. Although free diagnosis and care is offered in the public sector, only half of the estimated number of people with tuberculosis are diagnosed, treated, and notified to the national program. Private sector engagement strategies often have been small scale and time limited. We evaluated a Social Enterprise Model combining external funding and income generation at three tuberculosis screening centres across the Dhaka Metropolitan Area for diagnosing and treating tuberculosis. Methods and findings: The model established three tuberculosis screening centres across Dhaka Metropolitan Area that carried the icddr,b brand and offered free Xpert MTB/RIF tests to patients visiting the screening centres for subsidized, digital chest radiographs from April 2014 to December 2017. A network of private and public health care providers, and community recommendation was formed for patient referral. No financial incentives were offered to physicians for referrals. Revenues from radiography were used to support screening centres’ operation. Tuberculosis patients could choose to receive treatment from the private or public sector. Between 2014 and 2017, 1,032 private facilities networked with 8,466 private providers were mapped within the Dhaka Metropolitan Area. 64, 031 patients with TB symptoms were referred by the private providers, public sector and community residents to the three screening centres with 80% coming from private providers. 4,270 private providers made at least one referral. Overall, 10,288 pulmonary and extra-pulmonary tuberculosis cases were detected and 7,695 were bacteriologically positive by Xpert, corresponding to 28% of the total notifications in Dhaka Metropolitan Area. Conclusion: The model established a network of private providers who referred individuals with presumptive tuberculosis without financial incentives to icddr,b’s screening centres, facilitating a quarter of total tuberculosis notifications in Dhaka Metropolitan Area. Scaling up this approach may enhance national and international tuberculosis response.
- Open Access
- 12 October 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (10) , e0240250
Multicenter analysis of sputum microbiota in tuberculosis patients
The impact of tuberculosis and of anti-tuberculosis therapy on composition and modification of human lung microbiota has been the object of several investigations. However, no clear outcome has been presented so far and the relationship between M. tuberculosis pulmonary infection and the resident lung microbiota remains vague. In this work we describe the results obtained from a multicenter study of the microbiota of sputum samples from patients with tuberculosis or unrelated lung diseases and healthy donors recruited in Switzerland, Italy and Bangladesh, with the ultimate goal of discovering a microbiota-based biomarker associated with tuberculosis. Bacterial 16S rDNA amplification, high-throughput sequencing and extensive bioinformatic analyses revealed patient-specific flora and high variability in taxon abundance. No common signature could be identified among the individuals enrolled except for minor differences which were not consistent among the different geographical settings. Moreover, anti-tuberculosis therapy did not cause any important variation in microbiota diversity, thus precluding its exploitation as a biomarker for the follow up of tuberculosis patients undergoing treatment.
- 12 October 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (10) , e0240250
Open AccessMulticenter analysis of sputum microbiota in tuberculosis patients
The impact of tuberculosis and of anti-tuberculosis therapy on composition and modification of human lung microbiota has been the object of several investigations. However, no clear outcome has been presented so far and the relationship between M. tuberculosis pulmonary infection and the resident lung microbiota remains vague. In this work we describe the results obtained from a multicenter study of the microbiota of sputum samples from patients with tuberculosis or unrelated lung diseases and healthy donors recruited in Switzerland, Italy and Bangladesh, with the ultimate goal of discovering a microbiota-based biomarker associated with tuberculosis. Bacterial 16S rDNA amplification, high-throughput sequencing and extensive bioinformatic analyses revealed patient-specific flora and high variability in taxon abundance. No common signature could be identified among the individuals enrolled except for minor differences which were not consistent among the different geographical settings. Moreover, anti-tuberculosis therapy did not cause any important variation in microbiota diversity, thus precluding its exploitation as a biomarker for the follow up of tuberculosis patients undergoing treatment.